A kind of blood thinner can decrease risk of bleeding

In an industry-university cooperation, researchers developed an antibody that can prevent the formation of blood clots but does not trigger bleeding. Bleeding is a serious risk associated with a currently-used blood thinner.

The study was carried out on a variety of animal models using recombinant proteins such as recombinant dog proteins. In order to prepare the safe drug use in human body in the future, they also developed a second antibody which can quickly reverse the effects of the former drug, thus providing additional security measures to guard. Blood clots can cause heart attack, stroke and other cardiovascular diseases. Patients suffering from these diseases often use drugs to prevent blood clots, but it will bring a high risk of uncontrolled bleeding. Coagulation Factor XIa (FXIa) is the protein which plays a key role in the formation of blood clots. It has become a major drug target, but to achieve specifical inhibition of FXIa remains difficult.

Therefore, Tovo David and colleagues designed an antibody which is capable of binding specifically to FXIa and block activity of FXIa enzyme. The antibody can prevent blood clotting in the human body as well as mice and rabbits. The drug seems to be safe in the body of monkeys, because even giving dose which is much higher than required dose to prevent the formation of blood clots in monkeys, the monkeys didn't show signs of spontaneous bleeding. Although there is no increase in bleeding was found in these animal studies, FXI deficiency may be associated with bleeding in human body. Thus, the researchers developed a second antibody which can act as antidote that can rapidly reverse the activity of anti-FXIa antibody.

Through further research, reversible FXIa specific antibodies may provide a novel and potentially safer anticoagulants. Flarebio offers recombinant proteins of good quality such as recombinant Stim2.